

# OPTICEPT TECHNOLOGIES PUBLISHES SUPPLEMENTARY PROSPECTUS

The Board of Directors of OptiCept Technologies AB ("OptiCept" or the "Company") has prepared a supplementary prospectus (the "Supplementary Prospectus") to the EU Growth Prospectus approved and registered by the Swedish Financial Supervisory Authority and published by the Company on 8 November 2024 (the "Prospectus"). The Supplementary Prospectus has today been approved by the Swedish Financial Supervisory Authority and has been published on the Company's website and in other channels.

The Supplementary Prospectus has been prepared due to the fact that OptiCept, on 12 November 2024, announced through a press release that the Company's partner, Food Process Solutions ("FPS"), has called for the delivery of more OPTICEPT units on the order placed with the Company in May 2024, corresponding to 38 per cent of the total order value, and that FPS is financing the volume purchases of materials for cost reduction and short lead times. In total, FPS has thus called for a total of 44 per cent of the total order value. The press release is available on the Company's website, www.opticept.se.

The Supplementary Prospectus has been prepared in accordance with Article 23 of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the "Prospectus Regulation") and has today been approved and registered by the Swedish Financial Supervisory Authority. The Supplementary Prospectus is a part of, and should in all respects be read in conjunction with, the Prospectus. The Prospectus and the Supplementary Prospectus (together the "Prospectuses") are available on the Company's website, www.opticept.se, and Aqurat's website, www.aqurat.se. The Supplement Prospectus will also be available on the Swedish Financial Supervisory Authority's website, www.fi.se.

Investors who, prior to the publication of the Supplementary Prospectus, have subscribed or otherwise consented to subscription of shares in the rights issue announced on 18 October 2024 (the "Rights Issue") have, according to Article 23 of the Prospectus Regulation, the right to withdraw their subscription or consent within two business days from the publication of the Supplementary Prospectus, i.e. up to and including 19 November 2024. Withdrawal shall be made in writing to Aqurat Fondkommission AB, Subject: OptiCept Technologies AB, P.O. Box 7461, SE-103 92 Stockholm, Sweden, or by e-mail to <code>info@aqurat.se</code>. Investors who have applied for subscription of shares through a nominee shall contact their nominee regarding the withdrawal. Subscriptions that are not withdrawn within the specified time will remain binding and if investors wish to continue to subscribe for shares, they do not need to take any action.



For complete terms and conditions and other information about the Rights Issue, please refer to the Prospectuses.

#### Advisors

Corpura Fondkommission AB (www.corpura.se) is acting as financial advisor and Setterwalls Advokatbyrå AB is acting as legal advisor to OptiCept in connection with the Rights Issue. Aqurat Fondkommission AB is acting as issuing agent.

#### For more information:

Thomas Lundqvist, VD +46 73 268 05 70

Thomas.Lundqvist@opticept.se

Déspina Georgiadou Hedin, CFO +46 76 569 78 73 Despina.georgiadou@opticept.se

This information was submitted for publication, through the agency of the contact person set out above, at 15:20 CET on 15 November 2024.

### About OptiCept Technologies AB (publ)

OptiCept Technologies AB (publ) provides the food and plant industry with technological solutions that contribute to a more sustainable world and enable climate-smart economic growth. OptiCept optimizes biological processes - Increased extraction from raw material, extended shelf life, reduced waste, and improved quality (taste, aroma, color, nutritional content) of the final product.

The positive effects of technology increase efficiency for our customers, better products for the consumers, and minimal impact on our environment. Through patented technology in PEF (pulsed electric field) and VI (Vacuum Infusion), the technology opens up new business opportunities for the food and plant industry worldwide. OptiCept's vision is to contribute to a sustainable world by offering efficient green cutting-edge technology that is easy to use in the areas of FoodTech and PlantTech.

The Company is located in Lund and the share is traded on the Nasdaq First North Growth Market (ticker: OPTI). The Company's Certified Adviser is Carnegie Investment Bank AB (publ).

## IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in OptiCept. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for shares in OptiCept will only be made through the Prospectuses that OptiCept published on 8 November 2024 and 15



November 2024, respectively. The Prospectuses have been approved and registered by the Swedish Financial Supervisory Authority and have been published on the Company's website, **www.opticept.se**. The approval of the Prospectuses by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the Company's shares or any other securities.

This release is not a prospectus in accordance with the definition in the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares or other securities in OptiCept. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectuses. Thus, investors are encouraged to review the Prospectuses in their entirety. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in OptiCept have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

Within the European Economic Area ("EEA"), no public offering of shares or other securities (" Securities") is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the Prospectus Regulation which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to



investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain forward-looking statements which reflect the Company's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development, and the actual outcome could differ materially from the forward-looking statements.

**Attachments** 

OptiCept Technologies publishes supplementary prospectus